2-pyrrolino-camsirubicin

2-pyrrolino-camsirubicin is an investigational **anthracycline small-molecule antineoplastic** being developed by Monopar as a next-generation analog of camsirubicin. Public disclosures identify it with the code name **MNPR-202** and describe it as retaining the potentially non-cardiotoxic backbone of camsirubicin while introducing additional structural modifications intended to improve activity in tumors resistant to doxorubicin or camsirubicin. Based on its relationship to the anthracycline class and available preclinical descriptions, its antitumor activity is understood to derive from **DNA intercalation and inhibition of topoisomerase II**, producing DNA damage and apoptosis; preclinical lymphoma data also suggest a distinct immunomodulatory response profile relative to doxorubicin. Development appears to remain **preclinical/early-stage** for oncology indications rather than approved for any use.

Other names

2-pyrrolino-camsirubicin